

Cost-Effectiveness of Immune Checkpoint Inhibition and Targeted Treatment in Combination as Adjuvant Treatment of Patient with BRAF-Mutant Advanced Melanoma

Sini Li (✉ sli198@sheffield.ac.uk)

The University of Sheffield <https://orcid.org/0000-0002-1347-4024>

Xiaomin Wan

Second Xiangya Hospital

LiuBao Peng

Second Xiangya Hospital

YaMin Li

Second Xiangya Hospital

JianHe Li

Second Xiangya Hospital

Research Article

Keywords: Advanced melanoma, Cost-effectiveness, Immunotherapy, Microsimulation

Posted Date: August 1st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1773968/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Health Services Research on January 18th, 2023. See the published version at <https://doi.org/10.1186/s12913-023-09058-7>.

Abstract

Background: Immune checkpoint inhibitors (ICIs) and targeted treatments have improved the health outcomes of patients with advanced melanoma. However, due to the high cost of novel therapies, it is crucial to evaluate their value by considering both effectiveness and cost.

OBJECTIVE To compare the cost-effectiveness of these novel agents (atezolizumab-vemurafenib-cobimetinib, vemurafenib-plus-cobimetinib, dabrafenib-plus-trametinib, and encorafenib-plus-binimetinib) for first-line treatment of metastatic melanoma with the BRAF^{V600} mutation.

Methods: A patient-level model was developed to project the health outcomes of 4 strategies for patients with advanced melanoma. We estimated transition probabilities from the IMspire150 (ClinicalTrials.gov, NCT02908672), COMBI-AD (NCT01682083), and COLUMBUS (NCT01909453) trials using a parametric survival model. All health outcomes, including direct cost, quality-adjusted life-years (QALYs) and the incremental cost-effectiveness ratio (ICER), were estimated from the US payer perspective. Lifetime cost, QALYs, life-years (LYs), and ICERs were calculated. Univariable and probabilistic sensitivity analyses were performed to test model robustness, along with multiple scenario analyses.

Results: Of the 4 competing strategies, atezolizumab-vemurafenib-cobimetinib produced the best health outcomes, and the vemurafenib-cobimetinib strategy was the least expensive option. Atezolizumab-vemurafenib-cobimetinib, dabrafenib-plus-trametinib, and vemurafenib-cobimetinib formed the cost-effective frontier, indicating that the ordered ICERs were \$325113/QALYs for dabrafenib-plus-trametinib vs. vemurafenib-cobimetinib strategies and \$2247500/QALYs for atezolizumab-vemurafenib-cobimetinib vs. dabrafenib-plus-trametinib strategies. Encorafenib-plus-binimetinib was dominated by the other 3 competing strategies. The drug price and first-line utility significantly influenced the model outcomes.

Conclusion: For BRAF-mutant advanced melanoma, the vemurafenib-cobimetinib strategy could be considered the most cost-effective treatment at the willingness-to-pay threshold of \$150,000.

Background

Melanoma is the 5th most common cancer in the United States, with over 100,350 new cases diagnosed and approximately 6,850 deaths occurring in 2020.¹ The mortality risk related to melanoma is proportional to the depth of the primary tumor²; although approximately 98% of patients with localized early-stage melanoma survive for five years or more after disease diagnosis, the 5-year survival rate for advanced melanoma is only 10% in the US.^{3,4} BRAF, as the most commonly mutated gene, leads to a high mutation burden for patients with melanoma (approximately 50% of patients with metastatic melanoma have BRAF mutations).^{5,6}

While surgical excision is the main therapy for localized early-stage disease, unresectable and advanced melanoma is managed with diverse therapeutic options.⁷ These novel therapies, including immune checkpoint inhibitors (ICIs) (nivolumab and atezolizumab) and targeted treatments (dabrafenib,

vemurafenib, and encorafenib as BRAF inhibitors and trametinib, cobimetinib, and binimetinib as MEK inhibitors), were approved by the US Food and Drug Administration in recent years and have significantly improved the treatment landscape for metastatic melanoma.^{8–11}

More recent studies have reported that combinations of treatments with different mechanisms can improve efficacy, safety, and tolerability.^{9,12} In a phase III, randomized, double-blind trial (IMspire150), Gutzmer et al evaluated the safety and efficacy of the combination of ICIs (atezolizumab) with BRAF plus MEK inhibitors (vemurafenib-plus-cobimetinib) in patients with advanced BRAF^{V600} mutation-positive melanoma.⁹ The trial demonstrated that progression-free survival (PFS) was significantly prolonged in the study group (atezolizumab, vemurafenib, and cobimetinib) versus the control group (placebo, vemurafenib, and cobimetinib) (15.1 vs. 10.6 months; hazard ratio [HR] 0.78; 95% confidence interval [CI] 0.63–0.97). With the risk of adverse events (AEs) and discontinuation of treatment due to AEs being virtually similar between the study and control groups, it was concluded that the study group had no additional safety concerns to note.

Over nearly a decade, the cost of novel cancer agents has increased at unprecedented rates.¹³ The cost of melanoma treatment in the US is projected to reach \$3.16 billion by 2020, a 34% increase from 2010.³ Although previous studies have confirmed that the combination of ICIs with BRAF plus MEK inhibitors dramatically improves health outcomes in patients with BRAF^{V600} mutation-positive melanoma, it is still unknown whether considerable drug prices and intolerant AEs could be balanced by enhanced health benefits. Under the current healthcare setting, there is an increasing need to evaluate the value of different drugs in cancer in terms of both efficacy and cost to provide reasonable evidence for patients, physicians, and policy makers.

Therefore, the objective of this study was to estimate the cost-effectiveness of a combination treatment of BRAF plus MEK inhibitors with or without ICI treatments as a first-line adjuvant treatment for BRAF-mutant advanced melanoma from the US payer perspective.

Methods

Analytic Overview

A microsimulation model was constructed to estimate the lifetime cost and health outcomes of 4 treatment strategies for patients with BRAF-mutant advanced melanoma by using TreeAge 2020 Software. (Fig. 1 &2) Each model cycle represented 28 days over a lifetime horizon. Based on the cohort enrolled in the respective randomized control trials (RCTs) published previously, we generated a 50,000 baseline sample of patients.^{9–11} Patients had a mean age of 54 years (calculated by averaging the mean age of the patients in the 3 RCTs), and all patients had BRAF mutation advanced melanoma.

Patients who were included in the model were treated with 1 of 4 frontline interventions: (1) atezolizumab-vemurafenib-cobimetinib, (2) vemurafenib-plus-cobimetinib, (3) dabrafenib-plus-trametinib,

or (4) encorafenib-plus-binimetinib. Patients were prescribed nivolumab as second-line treatment after disease progression, and finally, all patients were switched to the best supportive care (BSC) state until death. (Fig. 1) Dosing and administration schedules for all strategies were based on the respective RCTs and are listed in eTable 2 in the supplement.

The primary outcomes of the model included total cost, quality-adjusted life-years (QALYs) and life-years (LYs), which were used to estimate the incremental cost-effectiveness ratios (ICERs). We conducted this analysis from a US payer perspective, adjusting all the costs to 2021 U.S. dollars (USD) and discounting both cost and utilities by 3% annually.¹⁴ Moreover, a willingness-to-pay threshold (WTP) of \$150,000/QALY was applied in this cost-effectiveness analysis.¹⁵

Model Structure

The model was classified as four states: PFS, progress-disease (PD), discontinuation due to AEs, or death due to other causes. (Fig. 2) Patients were decided to remain on current treatment or switched to next line therapy on the basis of transition probability which was estimated by using PFS or OS survival data obtained from previous respective studies.^{9-11, 16,17} The overall mortality rate (except for BSC state) during each line of active treatment corresponded to the transition probability for death state, calculated as the background mortality rate from the 2017 US Life Table 1⁸ and treatment-related serious AEs from RCTs.^{9-11, 16} (The US Life Table is listed in eTable 3 in the supplement.) As same as previous study, we applied Formula 1 as follows to transform the rates in the Life Table and treatment-related serious AEs to the transition probability.¹⁹ The minimum value was taken between the probability for death state and 1.²⁰ Based on the mortality data for metastatic melanoma, the probability of death from the BSC state was calculated by implementing the standard extrapolation method derived by Guyot et al.²¹ Briefly, we extracted the data points from each OS Kaplan-Meier curve from the respective RCT to generate pseudoindividual patient-level data by using Getdata digital software.¹⁷ These reconstructed survival data were then used to fit 4 standard parametric models (log-logistic, Weibull, lognormal, and exponential). On the basis of the goodness-of-fit method (Akaike information criterion), we selected the most appropriate survival distribution to estimate the transition probability.

$$P = 1 - \exp \{-r t\} \quad \text{Formula 1}$$

*The P is representing the probability; r is the rate; and t is the time.

The probabilities of patients remaining on current treatment or progressing to subsequent therapy were estimated on the basis of the PFS curves derived from respective RCTs using the same approach as the transition probabilities of OS.⁹⁻¹¹ The fitting results showed that log-logistic distribution was the optimal survival distribution for all PFS and OS curves. The fitting curves of PFS and OS are presented in eFigures 4 to 9 in the supplementary material. The transition probability of the event was calculated by using 1 to minus the ratio of the survivor function at the end of the interval to the survivor function at the beginning of the interval.¹⁹ (Formula 2) And the survival function of log-logistic is represented in Formula 3, so

Formula 2 could be rewritten to the probability density function of log-logistic as follows.¹⁹ (Formula 4)
We also considered discontinuation of treatment related to AEs, with transition probabilities obtained from the literature.⁹⁻¹¹ All the estimated transition probabilities are displayed in Table 1.

Table 1
Input parameters of model.

Parameters	Mean	Range	distribution	Reference
Survival model of PFS in the full cohort				
Atezolizumab + vemurafenib + cobimetinib	Shape = 1.375; Scale = 13.807		Loglogistic	9
Vemurafenib + cobimetinib	Shape = 1.663; Scale = 10.926		Loglogistic	9
Dabrafenib + trametinib	Shape = 1.4075; Scale = 12.9753		Loglogistic	11
Encorafenib + binimetinib	Shape = 1.668; Scale = 14.080		Loglogistic	10
Nivolumab	Shape = 1.2021; Scale = 4.6024		Loglogistic	16
OS in the best support care	Shape = 1.757; Scale = 7.007		Loglogistic	17
Probability of treatment discontinuation as a result of AE (%)				
Atezolizumab + vemurafenib + cobimetinib	13		Beta	9
Vemurafenib + cobimetinib	16		Beta	9
Dabrafenib + trametinib	26		Beta	11
Encorafenib + Binimetinib	13		Beta	10
Nivolumab			Beta	16

^a The range is the reported or estimated 95% CI.

Parameters	Mean	Range	distribution	Reference
Probability of treatment mortality as a result of AE (%)				
Atezolizumab + vemurafenib + cobimetinib	NA		Beta	9
Vemurafenib + cobimetinib	NA		Beta	9
Dabrafenib + trametinib	1.5		Beta	11
Encorafenib + Binimetinib	0		Beta	10
Nivolumab	0		Beta	16
Probability of background death	-	-	-	18
Drug cost, \$ (per mg)				
Atezolizumab	7.82	6.26–9.38	Gamma	22
Vemurafenib	0.16	0.13–0.19	Gamma	23–25
Cobimetinib	4.32	3.46–5.18	Gamma	23–25
Dabrafenib	0.89	0.71–1.07	Gamma	23–25
Trametinib	144.95	115.96-173.94	Gamma	23–25
Encorafenib	0.89	0.71–1.07	Gamma	24–26
Binimetinib	4.63	3.70–5.56	Gamma	24,25,27
Nivolumab	28.54	22.83–32.25	Gamma	22
Cost of best support care	4319	3455.2-5182.8	Gamma	29
Management of AEs, \$				
Atezolizumab + vemurafenib + cobimetinib	972	687.6-1166.4	Gamma	30
Vemurafenib + cobimetinib	1080	864–1296	Gamma	30
Dabrafenib + trametinib	1229	921-1536 ^a	Gamma	29
Encorafenib + Binimetinib	1587	1269.6-1904.4	Gamma	30

^a The range is the reported or estimated 95% CI.

Parameters	Mean	Range	distribution	Reference
Nivolumab	2688	2150.4-3225.6	Gamma	25
Administration cost				
IV infusion, single or initial drug (≤ 1 hour)	148.3	118.64-177.93	Gamma	28
Utilities				
Complete/partial response	0.88	0.70-1.00	Beta	4
Stable disease	0.80	0.64-0.96	Beta	4
Progressive disease	0.52	0.42-0.62	Beta	4
Disutility due to AEs (grade ≥ 3)	0.077	0.074-0.08 ^a	Beta	29
Average patient weight (kg)	70		Normal	4
Terminal care, \$	17346	13009-21682 ^a	Gamma	29
^a The range is the reported or estimated 95% CI.				

$$tp(t_u) = 1 - S(t) / S(t - u) \text{ Formula 2}$$

$$S(t) = [1 + (t/\gamma)^\lambda]^{-1} \text{ Formula 3}$$

$$f(t) = \frac{\left(\frac{t}{\gamma}\right)^\lambda - \left(\frac{t-u}{\gamma}\right)^\lambda}{1 + \left(\frac{t}{\gamma}\right)^\lambda} \text{ Formula 4}$$

*the γ is representing the shape of the distribution and the λ parameter regarded as the scale.

Costs and Utilities

All the model input parameters, including the costs and utilities, are listed in Table 1. In this model, we incorporated only direct costs, including drugs, administration, BSC, management of AEs, and terminal care. The unit costs of atezolizumab and nivolumab were derived from the 2021 average sale price from the Centers for Medicare & Medicaid Services (CMS).²² The prices of oral drugs, including vemurafenib, cobimetinib, dabrafenib, trametinib, encorafenib, and binimetinib, were based on public databases and the literature.²³⁻²⁷ The 2021 average wholesale price from RED BOOK Online was discounted at a rate of 17% to account for contract pricing and to be consistent with evaluates for Medicare reimbursement.²⁴ Although the average patient weight is 74.7 kg in the US, a patient weight of 70 kg was used to calculate

the total cost of treatments so that the weight loss effects of the advanced disease could be taken into consideration.⁴ The administration fee was derived from the 2021 CMS Physician Fee Schedule.²⁸ The overall costs related to BSC, management of grade 3 or 4 AEs and terminal care were obtained from the published literature.^{25,29,30}

The mean utility for each health state was obtained from published analyses. We allocated a utility of 0.88 for patients who had a complete or partial response to therapy, 0.80 for patients in first-line treatment, and 0.52 for progressive disease.^{31,32} The utility decrement (-0.077) was also adopted to specify the reduction in the valued QALY for an adverse drug reaction.⁴ QALYs are a way to measure individual- or group-obtained health benefits (length of life), which are adjusted to reflect the quality of life. In this study, QALYs were estimated by calculating the years of life remaining for the patient with BRAF-mutant advanced melanoma following our predefined treatment sequences and weighing over the lifetime horizon with a quality-of-life score. In addition, 1 QALY is equal to 1 year of life in full health. The calculation of the LYs was the same as that of the QALYs; however, LYs was regarded as the health state of a patient in perfect health (the utility was equal to 1).

Sensitivity Analyses

Multiple sensitivity analyses were performed to test the uncertainty of the model and to evaluate the robustness of our outcomes. In the univariable sensitivity analyses, we varied the model parameters based on their upper and lower limitations by using their 95% CIs or changing them by 20% from baseline to examine the impact of variables on outcomes, in accordance with the existing approach.^{4,33,34} Moreover, a Monte Carlo simulation of 3000 iterations of 6000 patients was generated to perform probability sensitivity analyses (PSAs) by using suitable distributions to sample the key model parameters. Utilities were represented by beta distribution, costs by gamma, and weight and median starting age by normal distribution. Based on PSA, a cost-effectiveness acceptability curve (CEAC) was developed to portray the likelihood that a competing strategy would be considered a cost-effective option at different WTP thresholds for health benefits (QALYs).

We also incorporated 3 scenario analyses in this study. First, to evaluate the influence of survival curve extrapolations simulated in the model, the time horizon was varied in different time spans (10, 20, and 30 years). Second, we assumed that some patients would experience discontinuation and switch to the BSC state in a certain proportion (10–30%). Finally, the price of atezolizumab was decreased to 75%, 50%, or 25% of its original cost.

Results

Base-Case Analysis

In our examination of 4 therapy strategies incrementally (Table 2), the vemurafenib-plus-cobimetinib, dabrafenib-plus-trametinib, and atezolizumab-vemurafenib-cobimetinib strategies constituted the cost-

effective frontier (eFigure 1 in the supplement). eFigure 1 in the supplement depicted that the vemurafenib-plus-cobimetinib strategy had the lowest cost, and compared with this strategy, the dabrafenib-plus-trametinib strategy gained an incremental 0.32 QALYs with an additional cost of \$102116, which led to an ICER of \$325113/QALY and dominated the encorafenib-plus-binimetinib strategy. The encorafenib-plus-binimetinib strategy was also dominated by the atezolizumab-vemurafenib-cobimetinib strategy, which produced the greatest health outcomes with an extra 0.10 QALYs and \$227808 compared with the dabrafenib-plus-trametinib strategy. The ICER of the atezolizumab-vemurafenib-cobimetinib vs dabrafenib-plus-trametinib strategy over dabrafenib-plus-trametinib vs vemurafenib-plus-cobimetinib strategy was \$1922387/QALY.

Table 2
Base-Case results.

Strategy	Total cost	LY	QALY	ICER ^a
Vemurafenib + cobimetinib	353457	2.34	1.96	Dominate
Encorafenib + binimetinib	588988	2.64	2.22	Dominated
Dabrafenib + trametinib	455573	2.72	2.28	325113
Atezolizumab + vemurafenib + cobimetinib	683381	2.83	2.38	2247500
*LY = Life year; QALY = Quality-adjusted life year; ICER = Incremental cost-effectiveness ratio.				
^a The ICER was compared with the next-best nondominated option.				

Univariable Sensitivity and Probability Analyses

In the comparison between the dabrafenib-plus-trametinib and vemurafenib-plus-cobimetinib strategies, the univariable sensitivity analyses showed that the model outcome was significantly influenced by the cost of dabrafenib, utility of first-line treatment, and the cost of vemurafenib. In the comparison between the atezolizumab-vemurafenib-cobimetinib and vemurafenib-plus-cobimetinib strategies, the utility of first-line treatment, price of atezolizumab, and discount rate played a crucial role in the model outcomes. Other model parameters, such as the decrement utility and the cost of AE management, had a mild impact on our estimated ICER. The CEAC illustrated that vemurafenib-plus-cobimetinib has a 100% probability of being considered a cost-effective option at a WTP threshold of \$150,000/QALY when compared with the other 3 competing strategies (Fig. 3).

Scenario Analyses

The first scenario analyses determined that although most of the total costs (95%) were produced in the first 5 years of the time horizon, which resulted in the ICERs of the first 5 years being higher than the base-case results, patients continued to obtain health benefits after 5 years. The ICERs changed slightly when we varied the time horizon to 10 and 20 years, and with increasing treatment duration, the ICERs decreased. A small percentage of patients switched to the BSC phase after disease progression from first-

or second-line therapy rather than receiving next-line treatment. In the second scenario, analyses showed that adjusting for the small proportion of patients switched to the BSC state did not dramatically change our model conclusions, with ICERs for the atezolizumab-vemurafenib-cobimetinib versus vemurafenib-plus-cobimetinib strategies of \$745702/QALY and \$720376/QALY when simulating 30% and 10% of individuals transitioning to the BSC phase, respectively. In our final scenario analyses, we demonstrated that although decrements in the costs for atezolizumab used in the first-line therapy of 25%, 50% and 75% would result in lower ICERs of 266193/QALY, \$443793/QALY, and 611481/QALY, respectively, it is still unlikely for atezolizumab-vemurafenib-cobimetinib versus vemurafenib-plus-cobimetinib strategies to be considered a cost-effectiveness option. All the scenario analysis outcomes are listed in eTable 4 in the supplement.

Discussion

After the results of several respective RCTs, the Food and Drug Administration (FDA) approved combination vemurafenib-plus-cobimetinib, dabrafenib-plus-trametinib, and encorafenib-plus-binimetinib for patients with melanoma, and this adjuvant treatment became a new standard of care for patients with BRAF-mutant melanoma. Compared with 20 years ago, the annual total medical expenditure of melanoma increased from \$249 million to over 600 million, which might be associated with a high cost of diagnosis, drug acquisition, treatment of metastases, AE management and end-of-life care.^{2,35-38} Unlike the regulatory body of the United Kingdom (the National Institution for Health and Care Excellence), the FDA did not take cost-effectiveness into consideration when making decisions concerning drug approval.³⁹ Therefore, CMS also does not take into account cost-effectiveness when making decisions regarding reimbursement and coverage.³⁹ Although immunotherapy dramatically enhances health outcomes in patients with BRAF-mutant melanoma, the optimal combination of immune-based treatments is still unknown from a value standpoint.

This study reveals that among the 4 competing arms, the upfront use of atezolizumab-vemurafenib-cobimetinib maximized health outcomes, followed by the dabrafenib-plus-trametinib and vemurafenib-cobimetinib strategies. Although these 3 strategies constituted the frontier line, they could not be regarded as the cost-effectiveness option because the ICER significantly exceeded the US WTP threshold.

To our knowledge, this is the first cost-effectiveness analysis incorporating different adjuvant treatment strategies for patients with BRAF-mutant melanoma. In addition, this study has multiple important strengths. First, this study was conducted on the basis of a series of randomized, double-blind phase III clinical trials. Second, we predefined appropriate frontline treatment to reflect the current standard of care and most advances in the treatment of BRAF-mutant melanoma. Third, we considered the AEs in the model, incorporating not only treatment discontinuation or death because of AEs but also the costs and decrement utility associated with medical toxicity. Fourth, our model could better reflect the heterogeneity of patients by using a microsimulation model. Finally, our assumption helps this study represent clinical practice more appropriately. For example, we assumed that a certain proportion of patients will switch to the BSC state instead of receiving next-line treatment.

This study also had some limitations that should be considered. First, we developed an indirect comparison between each strategy by obtaining data from multiple respective RCTs due to the paucity of head-to-head data. Although it would bring some biases to our model due to the difference in patient characteristics, this method was widely applied in economic analysis studies^{40–42}, and we validated the survival curves we fitted in our model (eFigures 4–9 in the supplement). Therefore, we appeal for a more direct comparison study in the future, and if the data of real-world data or long-term RCTs are available, we will update our conclusion. Second, our study did not incorporate adjuvant treatment (BRAF inhibitor + MEK inhibitor) as a second-line therapy because of a lack of data. Of the included RCTs, only the COLUMBUS trial had a small proportion of patients who had received previous treatment. As the RCT was conducted in the near future for patients with BRAF-mutant melanoma, future economic analyses should take adjuvant treatment as second-line treatment into account in the decision-making process. Finally, although the health utilities we used in the model were derived from a previously published cost-effectiveness study for advanced melanoma, it may not precisely reflect the patients we simulated in the model. Accuracy and robustness might be enhanced when utilities calculated for patients with BRAF-mutant melanoma in patients with immunotherapy are available in the future.

Conclusion

From the US payer perspective, the vemurafenib-plus-cobimetinib strategy could be regarded as the most cost-effective treatment for patients with BRAF-mutant advanced melanoma when we set the WTP threshold at 150,000/QALY compared with the other 3 competing strategies.

Declarations

Ethics approval and consent to participate: This is a model-based economic evaluation for which the patient data were all obtained from previous published studies. It does not contain any studies with animal or human participants.

Consent for publication: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Availability of data and material: All data generated or analyzed during this study are included in this published article/as Supplementary information files.

Competing interests: There is no conflict of interest between all authors.

Funding: This study was funded by the Health and Family Planning Commission of Hunan Province (No. 20200022) and the Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2021zzts1010).

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author Contributions:

Sini Li had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sini Li and Xiaomin Wan; Acquisition of data: Sini Li; Analysis and interpretation of data: Sini Li; Drafting of the manuscript: Sini Li and Xiaomin Wan; Critical revision of the manuscript for important intellectual content: Yamin Li; Statistical analysis: Sini Li; Obtaining funding: Jianhe Li and Sini Li; Administrative, technical, or material support: Jianhe Li and Liubao Peng; Supervision: Jianhe Li and Liubao Peng.

Acknowledgements: None.

References

1. National Cancer Institute. SEER cancer statistics factsheets: kidney and renal pelvis cancer. Available from: <https://seer.cancer.gov/statfacts/html/kidrp.html> Accessed March 2, 2021.
2. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. *In Vivo*. 2014;28(6):1005–11.
3. Almutairi AR, Alkhatib NS, Oh M, et al. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. *JAMA Dermatol*. 2019;155(1):22–8.
4. Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR. Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma. *J Clin Oncol*. 2017;35(11):1194–202.
5. American Cancer Society. Cancer treatment & survivorship facts & Figs. 2016–2017 (2016). Accessed April 11, 2021.
6. Tarhini A, Benedict A, McDermott D, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. *Immunotherapy*. 2018;10(14):1241–52.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology on melanoma. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf Published 2021. Accessed April 11, 2021.
8. Malissen N, Grob JJ. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. *Drugs*. 2018;78(12):1197–209.
9. Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet (London England)*. 2020;395(10240):1835–44.

10. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2018;19(10):1315–27.
11. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med*. 2017;377(19):1813–23.
12. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. *Clin Cancer Res*. 2014;20(24):6258–68.
13. Dolgin E. Bringing down the cost of cancer treatment. *Nature*. 2018;555(7695):26–9.
14. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. *Jama*. 1996;276(15):1253–8.
15. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the \$50,000-per-QALY threshold. *N Engl J Med*. 2014;371(9):796–7.
16. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015;16(4):375–84.
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711–23.
18. Arias E. United States Life, Tables. 2017. *Natl Vital Stat Rep*. 2019;68(7):1–66.
19. Caldwell D., Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. *Int J Epidemiol*. 2007;36(2):476–7.
20. Li S, Li J, Peng L, Li Y, Wan X. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies. *Front Pharmacol*. 2021;12:718014.
21. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res Methodol*. 2012;12:9.
22. 2021 ASP Drug Pricing Files.2021. Available from: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2021ASPFiles.html>. Accessed February 25, 2021.
23. RED BOOK online. IBM Micromedex; IBM Corporation. Accessed March 1. 2021. <http://www.micromedexsolutions.com>.
24. U.S. Congressional Budget Office. Prescription drug pricing in the private sector. Pub. No. 2703. January 2007. Available at: <https://pdfs.semanticscholar.org/0e4f/3b6aabb2f8d7dfc8f41d26ac6216ab7daf90.pdf>. Accessed April 7, 2021.
25. Oh A, Tran DM, McDowell LC, et al. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. *J managed care specialty Pharm*. 2017;23(6):653–64.

26. Patel KK, Stein S, Lacy J, O'Hara M, Huntington SF. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. *JAMA Netw Open*. 2021;4(1):e2033441.
27. Li S, Hu H, Ding D, Zhu Y, Huang J. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. *Adv therapy*. 2021;38(3):1650–9.
28. Centers for Medicare & Medicaid Services. 2021 Physician Fee Schedule. Available from: <https://www.cms.gov/apps/physician-fee-schedule>. Accessed March 4, 2021.
29. Wu B, Shi L. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data. *JAMA Dermatol*. 2020.
30. The Healthcare Cost and Utilization Project (HCUP). Available at: <https://www.hcup-us.ahrq.gov/>. Accessed April 5, 2021.
31. Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. *Health and quality of life outcomes*. 2014;12:140.
32. Beusterien KM, Szabo SM, Kotapati S, et al. Societal preference values for advanced melanoma health states in the United Kingdom and Australia. *Br J Cancer*. 2009;101(3):387–9.
33. Zhang Y, Baik SH, Fendrick AM, Baicker K. Comparing local and regional variation in health care spending. *N Engl J Med*. 2012;367(18):1724–31.
34. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. *Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2011;14(6):836–45.
35. Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. *Curr Med Res Opin*. 2015;31(8):1561–72.
36. Arondekar B, Curkendall S, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. *J managed care specialty Pharm*. 2015;21(2):158–64.
37. Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. *Melanoma Res*. 2014;24(6):602–10.
38. Guy GP Jr, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: a systematic review of the literature, 1990–2011. *Am J Prev Med*. 2012;43(5):537–45.
39. US Department of Health and Human Services. Patient Protection and Affordable Care Act of 2010. <http://www.hhs.gov/healthcare/about-the-law/read-the-law/index.html>.
40. Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. *J Clin Oncol*. 2021:JCO2001849.

41. Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. *Blood*. 2020;136(17):1946–55.
42. Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. *J Clin Oncol*. 2018;JCO1800122.

Figures




Figure 1

Treatment sequences.

*BSC = best support care.




Figure 2

Model structure.

*PFS = progression-free survival; PD = progressive disease; AEs = adverse events.




Figure 3

Acceptability Curves Comparing the Cost-Effectiveness of 4 Competing Strategies.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplement.docx](#)